MARKET

TPTX

Turning Point Therapeutics
TPTX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-11.6071
121.46
4.781
3,806,145,794.77
Bristol Myers' $4.1B Turning Point acquisition gets clearance in US, Germany, set to close
Bristol Myers Squibb's (NYSE:BMY) $4.1B <a href="http...
Seekingalpha · 08/16 11:45
Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of HSR Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Benzinga · 08/16 11:00
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
MT Newswires · 08/16 07:59
Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M misses by $2.15M
Turning Point Therapeutics press release (<s...
Seekingalpha · 08/08 20:46
BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc
BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc
Reuters · 07/27 22:16
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.
Benzinga · 07/27 20:45
Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of ROS1+ Advanced NSCLC
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the
Benzinga · 07/27 20:22
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDASAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developi...
GlobeNewswire · 07/27 20:05
More

Webull offers kinds of Turning Point Therapeutics stock information, including NASDAQ:TPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TPTX stock methods without spending real money on the virtual paper trading platform.